Bridgeway Capital Management’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.08M Buy
270,595
+5,578
+2% +$61K 0.06% 402
2026
Q2
$2.84M Buy
265,017
+70,000
+36% +$780K 0.05% 464
2026
Q1
$2.15M Buy
195,017
+134,939
+225% +$2.08M 0.04% 511
2025
Q4
$1.22M Buy
+60,078
New +$1.05M 0.03% 665

Other funds holding KROS

Bridgeway Capital Management's KROS Position: Q3 2026 in Review

Bridgeway Capital Management increased its Keros Therapeutics (KROS) stake by 2.1% in Q3 2026, buying an estimated $61K and bringing the position to 270,595 shares worth $3.08M. The position accounts for 0.06% of the portfolio, ranked #402.

Bridgeway Capital Management first reported a position in KROS in Q4 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Bridgeway Capital Management held 270,595 shares of Keros Therapeutics worth $3.08M as of Q3 2026.
  • Bridgeway Capital Management bought 5,578 Keros Therapeutics shares in Q3 2026, an estimated $61K.
  • Keros Therapeutics made up 0.06% of Bridgeway Capital Management's portfolio in Q3 2026, its #402 holding.
  • Bridgeway Capital Management first reported a position in Keros Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.